Early intra-articular corticosteroid injection is predictors of remission of juvenile idiopathic arthritis.


Journal

Minerva pediatrics
ISSN: 2724-5780
Titre abrégé: Minerva Pediatr (Torino)
Pays: Italy
ID NLM: 101777303

Informations de publication

Date de publication:
Jun 2023
Historique:
medline: 31 5 2023
pubmed: 14 9 2021
entrez: 13 9 2021
Statut: ppublish

Résumé

The aim of this study was to assess predictors of remission in children with juvenile idiopathic arthritis (JIA), treated with intra-articular corticosteroid injection (IACI) as monotherapy or in combination with methotrexate (MTX). A retrospective study of 43 patients diagnosed with different JIA subtypes and followed-up at a tertiary center between 2000 and 2014. We included patients treated with IACI as monotherapy or in combination with MTX at onset or thereafter. We excluded patients treated with MTX as monotherapy or in combination with biologics. Patients were divided into two groups on the basis of assigned treatment. Primary outcomes were disease remission and duration. We performed descriptive analysis, bivariate analysis and cross-correlation analysis between variables. Statistically significant results (P value <0.05) were chosen as variables for multivariate analysis. Median age of onset was 4.56 years (SD±3.85). Median time between disease onset and first IACI was 16.9 months (SD±34.7). We evaluated between time to remission in relation to age, time interval between onset and first IACI, time between onset and start of treatment with MTX, and time between first and second IACI. All of these were statistically significant (P value <0.05) in bivariate analysis, but time between onset and first IACI was the only statistically significant result, using multiple linear regression analysis. Therefore, in our study, 37 patients (86%) of patients went into remission on medication after a median disease duration of 48.8 months. We found that remission was related to time between onset and first IACI. Our predictive model showed that early IACI can be considered as a strong predictor of remission.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study was to assess predictors of remission in children with juvenile idiopathic arthritis (JIA), treated with intra-articular corticosteroid injection (IACI) as monotherapy or in combination with methotrexate (MTX).
METHODS METHODS
A retrospective study of 43 patients diagnosed with different JIA subtypes and followed-up at a tertiary center between 2000 and 2014. We included patients treated with IACI as monotherapy or in combination with MTX at onset or thereafter. We excluded patients treated with MTX as monotherapy or in combination with biologics. Patients were divided into two groups on the basis of assigned treatment. Primary outcomes were disease remission and duration. We performed descriptive analysis, bivariate analysis and cross-correlation analysis between variables. Statistically significant results (P value <0.05) were chosen as variables for multivariate analysis.
RESULTS RESULTS
Median age of onset was 4.56 years (SD±3.85). Median time between disease onset and first IACI was 16.9 months (SD±34.7). We evaluated between time to remission in relation to age, time interval between onset and first IACI, time between onset and start of treatment with MTX, and time between first and second IACI. All of these were statistically significant (P value <0.05) in bivariate analysis, but time between onset and first IACI was the only statistically significant result, using multiple linear regression analysis. Therefore, in our study, 37 patients (86%) of patients went into remission on medication after a median disease duration of 48.8 months.
CONCLUSIONS CONCLUSIONS
We found that remission was related to time between onset and first IACI. Our predictive model showed that early IACI can be considered as a strong predictor of remission.

Identifiants

pubmed: 34515444
pii: S2724-5276.21.06343-6
doi: 10.23736/S2724-5276.21.06343-6
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Methotrexate YL5FZ2Y5U1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

400-409

Auteurs

Federica Filosco (F)

Department of Clinical and Experimental Medicine, University of Catania, Catania Italy - federica.filosco@gmail.com.

Alessandro Giallongo (A)

Department of Clinical and Experimental Medicine, University of Catania, Catania Italy.

Salvatore Leonardi (S)

Department of Clinical and Experimental Medicine, University of Catania, Catania Italy.

Venera Tomaselli (V)

Department of Political and Social Sciences, University of Catania, Catania, Italy.

Patrizia Barone (P)

Department of Clinical and Experimental Medicine, University of Catania, Catania Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH